<DOC>
	<DOCNO>NCT00988858</DOCNO>
	<brief_summary>The primary purpose study evaluate safety LY2603618 combination pemetrexed side effect might associate along determine effect LY2603618 combination pemetrexed patient advanced metastatic Non-small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Advanced Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Must agree tumor biopsy screen Must diagnosis advance metastatic nonsquamous nonsmall cell lung cancer progress certain prior treatment Must available duration study willing follow study procedure If participant woman capable child , must negative pregnancy test within 7 day take first dose study drug Must discontinue radiation therapy least 4 week enter study Must take unapproved drug treatment indication within last 28 day start study treatment . Must pregnant lactating , consider become pregnant , consider father child . Males female reproductive potential must agree use medically approve contraceptive precaution trial patient 's physician considers safe become pregnant father child . Must know positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) . Must previously participate study involve LY2603618 Must previously take pemetrexed cancer Must know allergy LY2603618 pemetrexed Must currently infection may affect patient 's ability tolerate therapy Must serious medical condition disorder would make unsafe participate study uncontrolled diabetes chest pain due heart disease If take certain medication call nonsteroidal antiinflammatory drug ( NSAIDS ) , ibuprofen , must able stop take medication accord certain guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>